Austar Lifesciences Limited
AULSF
$0.07
$0.071,300.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.43% | -6.79% | -4.95% | -4.19% | -26.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.43% | -6.79% | -4.95% | -4.19% | -26.24% |
| Cost of Revenue | -5.76% | -7.11% | -7.06% | -6.32% | -26.62% |
| Gross Profit | -4.17% | -5.56% | 4.87% | 5.71% | -24.73% |
| SG&A Expenses | -1.67% | -3.09% | -18.53% | -17.88% | -38.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 17.90% | 19.08% | -207.54% | -209.92% | -67.91% |
| Total Operating Expenses | -5.71% | -7.07% | -9.83% | -9.11% | -29.26% |
| Operating Income | 4.34% | 2.84% | 151.72% | 152.14% | 257.37% |
| Income Before Tax | 230.35% | 225.59% | 142.94% | 143.28% | 239.04% |
| Income Tax Expenses | 34.06% | 32.13% | 267.50% | 268.80% | 149.28% |
| Earnings from Continuing Operations | 464.59% | 456.50% | 135.60% | 135.88% | 148.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -17.84% | -19.05% | -33.06% | -32.55% | 71.22% |
| Net Income | 325.97% | 319.86% | 113.93% | 114.04% | 114.24% |
| EBIT | 4.34% | 2.84% | 151.72% | 152.14% | 257.37% |
| EBITDA | 4.82% | 3.31% | 307.00% | 308.65% | 807.57% |
| EPS Basic | 325.00% | 325.00% | 114.14% | 114.14% | 114.29% |
| Normalized Basic EPS | 150.00% | 150.00% | 126.92% | 126.92% | 350.00% |
| EPS Diluted | 385.71% | 385.71% | 114.14% | 114.14% | 112.50% |
| Normalized Diluted EPS | 150.00% | 150.00% | 126.92% | 126.92% | 350.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |